Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice - PubMed (original) (raw)
. 2003 May 1;63(9):2079-87.
Affiliations
- PMID: 12727823
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice
Niels Reinmuth et al. Cancer Res. 2003.
Abstract
Members of the integrin family influence several aspects of tumor progression and metastasis, including cell survival, proliferation, and angiogenesis. Specific integrins such as alpha(v)beta(3) and alpha(v)beta(5) are involved in regulating endothelial cell function, and thus angiogenesis. We evaluated the effect of the alpha(v)beta(3)/alpha(v)beta(5) integrin antagonist S247 on the growth and angiogenesis of colon cancer liver metastases in an orthotopic murine model. Murine colon cancer cells were injected into the spleens of BALB/c mice to produce liver metastases. On day 7, miniature osmotic pumps were implanted into the subcutis to continuously infuse either saline or 70 mg/kg/day S247. All mice were sacrificed when control mice became moribund. Mice that received S247 developed significantly fewer liver metastases than did controls (P < 0.05). Using the same model, a subsequent survival study was performed. Mice were sacrificed when moribund as determined by an observer blinded to the treatment given. Treatment with S247 significantly prolonged overall survival (P < 0.05). Interestingly, primary tumors in the spleen were the cause of death in the S247-treated group as S247 appeared to have little effect on these tumors. Immunohistochemical staining demonstrated a significant reduction of vessels in liver metastases of S247-treated mice (P < 0.001), a significant increase in endothelial cell apoptosis (P < 0.05), and a significant decrease in pericyte coverage (P < 0.0001). To determine the role of S247 on angiogenesis, we examined the effect of S247 in vitro on human umbilical vein endothelial cells (HUVECs) and human vascular smooth muscle cells (hVSMCs). The addition of S247 to HUVECs and hVSMCs growing on vitronectin-coated flasks and in Matrigel significantly impaired cell growth and colony formation, respectively (P < 0.05). Furthermore, S247 completely inhibited the attachment of HUVECs and hVSMCs and increased apoptosis by six- to 9fold compared with controls. In in vitro invasion assays, S247-treated cells demonstrated decreased migration (P < 0.05). In conclusion, S247 demonstrated significant antimetastatic and antiangiogenic activity and impaired both endothelial and hVSMC/pericyte function in vitro and in vivo. The use of agents such as integrin antagonists that target multiple cell types involved in angiogenesis may be a more effective method of inhibiting angiogenesis than agents targeting only the endothelial cells.
Similar articles
- Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Bruns CJ, et al. Cancer. 2000 Aug 1;89(3):488-99. Cancer. 2000. PMID: 10931447 - Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM. Shaheen RM, et al. Cancer Res. 2001 Feb 15;61(4):1464-8. Cancer Res. 2001. PMID: 11245452 - Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE. Abdollahi A, et al. Clin Cancer Res. 2005 Sep 1;11(17):6270-9. doi: 10.1158/1078-0432.CCR-04-1223. Clin Cancer Res. 2005. PMID: 16144931 - A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Ellis LM. Ellis LM. Am Surg. 2003 Jan;69(1):3-10. Am Surg. 2003. PMID: 12575772 Review. - LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo.
Gao JJ, Xue X, Gao ZH, Cui SX, Cheng YN, Xu WF, Tang W, Qu XJ. Gao JJ, et al. Microvasc Res. 2011 Sep;82(2):122-30. doi: 10.1016/j.mvr.2011.05.008. Epub 2011 Jun 12. Microvasc Res. 2011. PMID: 21664364 Review.
Cited by
- The role of the extracellular matrix in angiogenesis in malignant glioma tumors.
Wang D, Anderson JC, Gladson CL. Wang D, et al. Brain Pathol. 2005 Oct;15(4):318-26. doi: 10.1111/j.1750-3639.2005.tb00117.x. Brain Pathol. 2005. PMID: 16389944 Free PMC article. Review. - Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.
Qiu Q, Wang Q, Deng C, Sun Y, Chen T, Guo L, Zhang F. Qiu Q, et al. Am J Cancer Res. 2016 Dec 1;6(12):2846-2858. eCollection 2016. Am J Cancer Res. 2016. PMID: 28042504 Free PMC article. - Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.
Rege TA, Fears CY, Gladson CL. Rege TA, et al. Neuro Oncol. 2005 Apr;7(2):106-21. doi: 10.1215/S115285170400119X. Neuro Oncol. 2005. PMID: 15831230 Free PMC article. Review. - Anti-cancer therapies targeting the tumor stroma.
Hofmeister V, Schrama D, Becker JC. Hofmeister V, et al. Cancer Immunol Immunother. 2008 Jan;57(1):1-17. doi: 10.1007/s00262-007-0365-5. Epub 2007 Jul 27. Cancer Immunol Immunother. 2008. PMID: 17661033 Free PMC article. Review. - Optical in vivo imaging detection of preclinical models of gut tumors through the expression of integrin αVβ3.
Marelli G, Avigni R, Allavena P, Garlanda C, Mantovani A, Doni A, Erreni M. Marelli G, et al. Oncotarget. 2018 Jul 31;9(59):31380-31396. doi: 10.18632/oncotarget.25826. eCollection 2018 Jul 31. Oncotarget. 2018. PMID: 30140377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical